PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections
Completed Production and Release of Three Process Validation Batches of D-PLEX100
Successful Completion of Good Manufacturing Practice Audit of Company’s Manufacturing Facility
Conference Call Scheduled for Today at
PETACH TIKVA, Israel,
Recent Corporate Highlights:
- A total of 20 centers are currently open in the ongoing SHIELD II Phase 3 trial that is recruiting patients undergoing open colorectal abdominal surgery with large incisions.
- Approximately 40 centers are expected to be open by the end of 2023.
- Unblinded interim analysis is planned to be conducted once approximately 400 patients complete their 30-day follow-up.
- Top-line results are expected in the second half of 2024.
- Achieved significant D-PLEX100 manufacturing-related milestones.
- Production and release of three process validation batches of D-PLEX100.
- Good Manufacturing Practice (GMP) audit of the Company’s manufacturing facility completed without any critical or major findings.
- Published positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals in the peer-reviewed journal,
International Journal of Toxicology . - Presented the results of the SHIELD I Phase 3 trial for the first time at a medical meeting, the
American College of Surgeons Clinical Congress 2023. - Appointed Nurit Tweezer-Zaks, MD, MBA, to Board of Directors following the retirement of
Anat Tsour Segal .- Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years.
- Regained compliance with Nasdaq’s Minimum Closing Bid Price Rule.
“Our ongoing SHIELD II Phase 3 trial for our promising lead product candidate, D-PLEX100, is progressing as anticipated,” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “We currently have 20 centers open, many of which have just recently begun recruiting patients, and we expect enrollment to ramp-up shortly. We anticipate having approximately 40 centers open by the end of 2023. Importantly, we continue to expect top-line results from
“While we focus on enrollment into
As to the current situation in
Financial results for three months ended
- Research and development (R&D) expenses for the three months ended
September 30, 2023 , were$3.8 million , compared to$6.2 million in the same three-month period of 2022. The decrease in R&D expenses resulted primarily from the completion of the SHIELD I Phase 3 clinical trial. - General and administrative (G&A) expenses for the three months ended
September 30, 2023 , were$1.2 million , compared to$1.7 million for the same period of 2022. - Marketing and business development expenses for the three months ended
September 30, 2023 , were$0.3 million , compared to$0.8 million for the same period of 2022. - For the three months ended
September 30, 2023 , the Company had a net loss of $5.6 million, or ($3.40 ) per share, compared to a net loss of$9.3 million , or ($14.19 ) per share, in the three-month period endedSeptember 30, 2022 .
Financial results for nine months ended
- R&D expenses, net for the nine months ended
September 30, 2023 , were$11.6 million , compared to$23.3 million for the same nine-month period of 2022. - G&A expenses for the nine months ended
September 30, 2023 , were$4.3 million , compared to$6.4 million for the same period of 2022. - Marketing and business development expenses for the nine months ended
September 30, 2023 , were$1.0 million , compared to$2.5 million for the same period of 2022. - The decreases in G&A and marketing and business development expenses were primarily due to the Company’s cost reduction plan announced in October 2022 and further cost savings initiatives implemented during the first nine months of 2023.
- For the nine months ended
September 30, 2023 , the Company had a net loss of $17.5 million, or ($13.59 ) per share, compared to a net loss of$33.0 million , or ($51.15 ) per share, in the nine-month period endedSeptember 30, 2022 .
Balance Sheet Highlights
- As of September 30, 2023, the Company had cash and cash equivalents and deposits in the amount of
$10.2 million .PolyPid expects that this cash balance will be sufficient to fund operations into late first quarter of 2024.
Conference Call Dial-In & Webcast Information:
| Date: | |
| Time: | |
| Q&A Participants: | https://register.vevent.com/register/BIbd0a9baa57b1427e809302152ba58bd3 |
| Webcast: | https://edge.media-server.com/mmc/p/r9ot5d24 |
About D-PLEX100
D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (SSIs). Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing open abdominal colorectal surgery with large incisions (>20cm).
About PolyPid
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the number of centers expected to open by the end of 2023, the expected timing of top-line data, the planned submission of a New Drug Application and EU Marketing Authorization Application regulatory filings, potential commercial demand for D-PLEX100 and the expected sufficiency of the Company’s cash balance. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 31, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
COO – US
908-858-5995
IR@Polypid.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
| INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||
| U.S. dollars in thousands | ||||||
| 2023 | 2022 | |||||
| Unaudited | Audited | |||||
| ASSETS | ||||||
| CURRENT ASSETS: | ||||||
| Cash and cash equivalents | $ | 1,353 | $ | 8,552 | ||
| Short-term deposits | 8,801 | 4,042 | ||||
| Restricted cash | 495 | 511 | ||||
| Prepaid expenses and other current assets | 473 | 1,089 | ||||
| Total current assets | 11,122 | 14,194 | ||||
| LONG-TERM ASSETS: | ||||||
| Property and equipment, net | 8,077 | 9,247 | ||||
| Operating lease right-of-use assets | 1,632 | 2,431 | ||||
| Other long-term assets | 101 | 99 | ||||
| Total long-term assets | 9,810 | 11,777 | ||||
| Total assets | $ | 20,932 | $ | 25,971 | ||
| INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
| 2023 | 2022 | |||||||
| Unaudited | Audited | |||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Current maturities of long-term debt | $ | 2,859 | $ | 4,024 | ||||
| Accrued expenses and other current liabilities | 2,024 | 2,429 | ||||||
| Trade payables | 529 | 1,141 | ||||||
| Current maturities of operating lease liabilities | 486 | 959 | ||||||
| Total current liabilities | 5,898 | 8,553 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Long-term debt | 7,665 | 7,574 | ||||||
| Deferred revenues | 2,548 | 2,548 | ||||||
| Long-term operating lease liabilities | 832 | 1,173 | ||||||
| Other liabilities | 451 | 294 | ||||||
| Total long-term liabilities | 11,496 | 11,589 | ||||||
| COMMITMENTS AND CONTINGENT LIABILITIES | ||||||||
| SHAREHOLDERS' EQUITY: | ||||||||
| Ordinary shares with no par value - | ||||||||
| Authorized: 107,800,000 and 47,800,000 shares at |
- | - | ||||||
| Additional paid-in capital | 235,491 | 220,273 | ||||||
| Accumulated deficit | (231,953 | ) | (214,444 | ) | ||||
| Total shareholders' equity | 3,538 | 5,829 | ||||||
| Total liabilities and shareholders' equity | $ | 20,932 | $ | 25,971 | ||||
*) On
| INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||
| Nine Months Ended | Three Months Ended | |||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||
| Operating expenses: | ||||||||||||||
| Research and development, net | $ | 11,560 | $ | 23,335 | $ | 3,806 | $ | 6,240 | ||||||
| Marketing and business development | 1,003 | 2,538 | 261 | 840 | ||||||||||
| General and administrative | 4,305 | 6,403 | 1,193 | 1,680 | ||||||||||
| Operating loss | 16,868 | 32,276 | 5,260 | 8,760 | ||||||||||
| Financial expense, net | 581 | 640 | 319 | 437 | ||||||||||
| Loss before income tax | 17,449 | 32,916 | 5,579 | 9,197 | ||||||||||
| Income tax expenses | 60 | 74 | 25 | 74 | ||||||||||
| Net loss | $ | 17,509 | $ | 32,990 | $ | 5,604 | $ | 9,271 | ||||||
| Basic and diluted loss per ordinary share *) | $ | 13.59 | $ | 51.15 | $ | 3.40 | $ | 14.19 | ||||||
| Weighted average number of ordinary shares used in computing basic and diluted loss per share | 1,288,678 | 644,958 | 1,650,259 | 653,240 | ||||||||||
*) On
Source: PolyPid Ltd.
